Analyst Price Targets — RGNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 10:13 am | — | H.C. Wainwright | $30.00 | $10.38 | TheFly | Regenxbio price target lowered to $30 from $32 at H.C. Wainwright |
| March 5, 2026 7:52 pm | Judah Frommer | Morgan Stanley | $17.00 | $8.72 | StreetInsider | Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley |
| February 10, 2026 2:05 pm | — | H.C. Wainwright | $32.00 | $8.92 | TheFly | Regenxbio price target lowered to $32 from $34 at H.C. Wainwright |
| February 10, 2026 1:50 pm | Brian Skorney | Robert W. Baird | $27.00 | $8.92 | TheFly | Regenxbio price target lowered to $27 from $39 at Baird |
| February 10, 2026 1:35 pm | — | UBS | $18.00 | $8.97 | TheFly | Regenxbio price target lowered to $18 from $25 at Morgan Stanley |
| February 10, 2026 11:23 am | — | Goldman Sachs | $12.00 | $10.31 | TheFly | Regenxbio price target lowered to $12 from $14 at Goldman Sachs |
| January 29, 2026 11:50 am | Yi Chen | H.C. Wainwright | $34.00 | $11.52 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) |
| January 27, 2026 9:29 pm | — | Barclays | $37.00 | $13.41 | TheFly | Regenxbio assumed with an Overweight at Barclays |
| December 19, 2025 12:49 pm | — | Stifel Nicolaus | $45.00 | $13.51 | TheFly | Regenxbio price target raised to $45 from $40 at Stifel |
| December 15, 2025 11:20 am | Mani Foroohar | Leerink Partners | $20.00 | $13.88 | StreetInsider | Regenxbio Inc. (RGNX) PT Raised to $20 at Leerink Partners |
Latest News for RGNX
LOS ANGELES, April 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are…
NEW YORK, April 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline. So what: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without…
New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that…
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The…
NEW YORK--(BUSINESS WIRE)---- $RGNX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RGNX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.